TRANSCODE THERAPEUTICS, INC.
  • Home
  • About
    • Who We Are
    • Leadership
    • Partnering
  • Focus
  • Science
  • Pipeline
    • Platform
    • TTX-MC138
    • Other Candidates
  • Resources
  • Investors
  • Careers

Partnering

Partnering

TransCode Therapeutics is actively seeking and engaging in diverse and extensive partnerships and collaborations with world-leading academic research institutes and biotechnology companies who share our vision to transform cancer medicine through RNA therapeutics. We seek and evaluate collaboration opportunities that complement our innovation and business strategies. ​

​Alliance with MD Anderson

TransCode recently announced a strategic alliance with MD Anderson to advance RNA therapies for oncology. Through the alliance, TransCode and MD Anderson scientists will collaborate on preclinical studies to further validate TransCode’s therapeutic and diagnostic candidates and to expand the reach of TransCode’s discovery engine. The results of these studies will inform future clinical trials with these agents, including trials to be led at MD Anderson. Learn more about this collaboration and all the TransCode news.

Partnering with TransCode

If you share our vision and passion for transforming cancer treatment, reach out. ​

    Request more information

Submit
Picture
TTX is an investigational platform encompassing therapeutic candidates (including TTX-MC138) and diagnostics which remain in development. Their safety and efficacy have not yet been evaluated by the FDA or any other regulatory agency.

Home

About

About
leadership

Partnering
​Careers     

Focus

Focus

Science

Science
​Resources

Pipeline

PIPELINE
TTX-MC138
​OTHER CANDIDATES

Contact/Support

Contact
​TERMS OF USE
PRIVACY POLICY
FCOI Policy
​
© TRANSCODE THERAPEUTICS, INC. 2022.​ ALL RIGHTS RESERVED.
  • Home
  • About
    • Who We Are
    • Leadership
    • Partnering
  • Focus
  • Science
  • Pipeline
    • Platform
    • TTX-MC138
    • Other Candidates
  • Resources
  • Investors
  • Careers